Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma
Blood Cancer J
.
2022 Jun 1;12(6):87.
doi: 10.1038/s41408-022-00680-y.
Authors
Ricardo D Parrondo
1
,
Zaid Abdel Rahman
2
,
Michael G Heckman
3
,
Mikolaj Wieczorek
3
,
Liuyan Jiang
4
,
Hassan B Alkhateeb
5
,
Mark R Litzow
5
,
Patricia Greipp
6
,
Taimur Sher
1
,
Leif Bergsagel
7
,
Rafael Fonseca
7
,
Vivek Roy
1
,
Angela Dispenzieri
5
,
Mohamed A Kharfan-Dabaja
1
,
Hemant S Murthy
1
,
Sikander Ailawadhi
1
,
James M Foran
8
Affiliations
1
Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA.
2
Stem Cell Transplantation and Cellular Therapies, MD Anderson Cancer Center, Houston, TX, USA.
3
Division of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, FL, USA.
4
Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL, USA.
5
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
6
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
7
Division of Hematology-Oncology, Mayo Clinic, Phoenix, AZ, USA.
8
Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA. Foran.James@mayo.edu.
PMID:
35650175
PMCID:
PMC9160012
DOI:
10.1038/s41408-022-00680-y
No abstract available
Publication types
Letter
MeSH terms
Humans
Lymphocytes
Multiple Myeloma* / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Grants and funding
P30 CA015083/CA/NCI NIH HHS/United States
P50 CA186781/CA/NCI NIH HHS/United States